Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. 2003. Progress in cancer screening practices in the United States: Results from the 2000 National Health Interview Survey. Cancer 97(6):1528-1540.

Takahashi H, Echizen H. 2003. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. The Pharmacogenomics Journal 3(4):202-214.

UK Department of Health. 2002. Drug Treatment for Multiple Sclerosis (Beta-Interferons and Glatiramer Acetate)—Risk Sharing Scheme. [Online]. Available: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/PrimaryCare/PrimaryCareTrusts/PrimaryCareTrustsArticle/fs/en?CONTENT_ID=4000556&chk=nvlrjJ [accessed September 2006].

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347(25):1999-2009.

Weinstein S, Obuchowski NA, Lieber ML. 2005. Clinical evaluation of diagnostic tests. American Journal of Roentgenology 184(1):14-19.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement